Omi Keron has a large number of escapes to the neutralization of antibodies
Science and Technology Daily, Beijing, December 28 (Reporter Zhang Mengran) According to a paper recently published in the British journal Nature, a team including scientists from the French Pasteur Institute recently isolated Omi Keron from a patient in Belgium. Virus, and analyzed the virus's sensitivity to 9 monoclonal antibodies that have been approved for clinical use or are still in development.
It was found that the Omi Keron mutant strain can completely or partially resist the neutralizing effect of all monoclonal antibodies in the experiment.
Among them, 5 kinds of antibodies (Bamlanivimab, Etesevimab, Casirivimab, Imdevimab and Regdanvimab) are not effective against Omi Keron; 2 antibodies (Cilgavimab and Andintrevimab) have a lower neutralizing activity against Omi Keron than their activity against delta. 20 times; Sotrovimab's anti-Omi Keron activity is about 3 times lower than its anti-delta activity.
In the serum collected from Pfizer vaccine (16 people) or AstraZeneca vaccinators (18 people) 5 months after the second injection, no antiviral activity against Omi Keron was detected.
From the serum samples from 20 people who received the third dose of Pfizer vaccine, the research team found that the neutralizing activity of Omi Keron increased by 6 times.
In the serum of 40 recovered patients (with a history of infection) collected 6 or 12 months after the onset of symptoms, the neutralizing activity of Omi Keron was either very low or not.
However, among the 22 people who had received a shot of Pfizer vaccine among these recovered patients, the neutralizing activity in their bodies was higher than that of those who had received two shots of vaccine without a history of infection.
These preliminary analyses are all based on the sera of vaccinators or those who have recovered from infection, but the research team pointed out that the sample size of these sera is relatively small, and they only analyzed two vaccines, Pfizer and AstraZeneca.
The analysis results indicate that antibody therapy may need to be quickly adjusted for Omi Keron, and the vaccine booster injection may enhance the neutralizing ability of Omi Keron.